Welcome to our dedicated page for ALFA S.A.B DE CV ORD A SH news (Ticker: ALFFF), a resource for investors and traders seeking the latest updates and insights on ALFA S.A.B DE CV ORD A SH stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ALFA S.A.B DE CV ORD A SH's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ALFA S.A.B DE CV ORD A SH's position in the market.
Alfa, S.A.B. de C.V. announced the successful receipt of requisite consents from holders of approximately 89.85% of its outstanding 6.875% Senior Notes due 2044. This allows the company to execute a supplemental indenture to amend the original indenture governing the Notes. The company will pay an Early Consent Fee of US$10.00 per US$1,000.00 principal amount to eligible holders who delivered valid consents before the Early Consent Deadline.
Additionally, Alfa plans to have Sigma Alimentos, S.A. de C.V. and certain subsidiaries provide a full and irrevocable guarantee of the Notes. Due to strong support, all outstanding Notes will benefit from these guarantees, maintaining the existing CUSIP numbers. The proposed amendments will become operative upon satisfaction of conditions, including shareholder approval of the spin-off of Alpek, S.A.B. de C.V.
